168 related articles for article (PubMed ID: 36435652)
1. Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma.
Choi SH; Kang I; Lee SH; Kang B; Cheon J; Kim DJ; Kim G; Kwon CI; Ko KH; Chon HJ
Surgery; 2023 Feb; 173(2):280-288. PubMed ID: 36435652
[TBL] [Abstract][Full Text] [Related]
2. NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Maithel SK; Keilson JM; Cao HST; Rupji M; Mahipal A; Lin BS; Javle MM; Cleary SP; Akce M; Switchenko JM; Rocha FG
Ann Surg Oncol; 2023 Oct; 30(11):6558-6566. PubMed ID: 37368098
[TBL] [Abstract][Full Text] [Related]
3. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).
Virchow I; Treckmann JW; Prasnikar N; Linden G; Markus P; Schumacher B; Albers D; Herold T; Ting S; Schmidt H; Radunz S; Wiesweg M; Siveke J; Schuler M; Kasper S
Oncol Res Treat; 2023; 46(3):89-99. PubMed ID: 36623497
[TBL] [Abstract][Full Text] [Related]
5. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Shroff RT; Javle MM; Xiao L; Kaseb AO; Varadhachary GR; Wolff RA; Raghav KPS; Iwasaki M; Masci P; Ramanathan RK; Ahn DH; Bekaii-Saab TS; Borad MJ
JAMA Oncol; 2019 Jun; 5(6):824-830. PubMed ID: 30998813
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study.
Nooijen LE; Franken LC; Belkouz A; Oulad Abdennabi I; Besselink MG; Busch OR; Swijnenburg RJ; Klümpen HJ; Erdmann JI
Am J Clin Oncol; 2021 Oct; 44(10):526-532. PubMed ID: 34469345
[TBL] [Abstract][Full Text] [Related]
9. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
Zhou N; Li X; Yang Y; Tan S; Zhang S; Huang Q; Gou H
BMC Cancer; 2023 Aug; 23(1):729. PubMed ID: 37550655
[TBL] [Abstract][Full Text] [Related]
11. Micro-lymph node metastasis in intrahepatic cholangiocarcinoma showing pathological complete response to primary tumor and intrahepatic metastasis treated by gemcitabine plus cisplatin chemotherapy and radical surgery.
Shibata Y; Sudo T; Tazuma S; Tazawa H; Suzuki T; Onoe T; Shimizu Y; Tashiro H; Kuraoka K; Takahashi S
Clin J Gastroenterol; 2023 Feb; 16(1):81-86. PubMed ID: 36239900
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
Jeong H; Kim KP; Jeong JH; Hwang DW; Lee JH; Kim KH; Moon DB; Lee MA; Park SJ; Chon HJ; Park JH; Lee JS; Ryoo BY; Yoo C
Hepatology; 2023 May; 77(5):1540-1549. PubMed ID: 37070950
[TBL] [Abstract][Full Text] [Related]
13. ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Maithel SK
Ann Surg Oncol; 2023 Oct; 30(11):6567-6568. PubMed ID: 37386309
[No Abstract] [Full Text] [Related]
14. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
[TBL] [Abstract][Full Text] [Related]
15. Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.
Jung K; Park J; Jung JH; Lee JC; Kim J; Hwang JH
Gut Liver; 2022 Sep; 16(5):798-805. PubMed ID: 35000934
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
Wirasorn K; Ngamprasertchai T; Khuntikeo N; Pakkhem A; Ungarereevittaya P; Chindaprasirt J; Sookprasert A
J Gastroenterol Hepatol; 2013 Dec; 28(12):1885-91. PubMed ID: 23829232
[TBL] [Abstract][Full Text] [Related]
17. [A Case of an Advanced Intrahepatic Cholangiocarcinoma Effectively Treated by Conversion Surgery after Neoadjuvant Chemotherapy of Gemcitabine, Cisplatin and S-1].
Ogura N; Hoshino M; Hayashi T; Odaira M; Harada H; Hirose S; Funakoshi S
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1665-1667. PubMed ID: 36733169
[TBL] [Abstract][Full Text] [Related]
18. A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy.
Sumiyoshi T; Uemura K; Shintakuya R; Okada K; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Arihiro K; Takahashi S
Clin J Gastroenterol; 2022 Dec; 15(6):1164-1168. PubMed ID: 36181621
[TBL] [Abstract][Full Text] [Related]
19. [A case of curative resection after downsizing chemotherapy in initially unresectable locally advanced intrahepatic cholangiocarcinoma].
Aoki Y; Suzuki T; Kato A; Shimizu H; Ohtsuka M; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takano S; Okamura D; Suzuki D; Sakai N; Kagawa S; Miyazaki M
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1509-11. PubMed ID: 25731235
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series.
Abdelrahim M; Al-Rawi H; Esmail A; Xu J; Umoru G; Ibnshamsah F; Abudayyeh A; Victor D; Saharia A; McMillan R; Al Najjar E; Bugazia D; Al-Rawi M; Ghobrial RM
Curr Oncol; 2022 May; 29(5):3585-3594. PubMed ID: 35621680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
